Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as a Single Agent and in Combination With Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Deruxtecan

NCT05954143 is registered in ClinicalTrials.gov with Bolt Biotherapeutics, Inc. as lead sponsor.

NCT NCT05954143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05954143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Multi-Center, Randomized, Open-Label Trial of BDC-1001 as a Single Agent and in Combination With Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Deruxtecan
Lead sponsor
Bolt Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2023
Completion date
September 25, 2024
Enrollment
11 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, metastatic breast cancer